becotatug vedotin + zimberelimab

Becotatug vedotin + zimberelimab is an investigational combination therapy comprising an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) and a programmed cell death protein 1 (PD-1) inhibitor. Becotatug vedotin (MRG003) consists of a humanized anti-EGFR monoclonal antibody conjugated to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. Upon binding to EGFR on the surface of cancer cells, the ADC is internalized, releasing MMAE to induce cell cycle arrest and apoptosis. Zimberelimab is a fully human monoclonal antibody that targets PD-1, preventing its interaction with PD-L1 and PD-L2 to restore and enhance T-cell-mediated anti-tumor immune responses. This combination is being evaluated for its potential synergistic efficacy in treating recurrent or metastatic squamous cell carcinomas of the cervix, vulva, and vagina, particularly in patients who have failed prior standard-of-care therapies.

Other names

MRG003 + zimberelimabMRG003 + GLS-010